🔍
Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+biologics
96
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Gas6-functionalized extracellular vesicles for treatment of inflammatory conditions
Value Proposition· Superior Anti-Inflammatory Potency: This membrane-associated GAS6 demonstrates over 10-fold higher anti-inflammatory activity compared to equivalent amounts of soluble recombinant GAS6 proteins. · Dual Mechanism of Action: Inhibits pro-inflammatory cytokine production and concurrently stimulates anti-inflammatory responses,...
Published: 1/22/2026
|
Inventor(s):
Kenneth Witwer
,
Matias Ostrowski
,
Martina Fabiano
,
Alan Adamczyk
Keywords(s):
Category(s):
Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms
,
Technology Classifications > Therapeutic Modalities > Targets
,
Technology Classifications > Therapeutic Modalities > Biologics
,
Clinical and Disease Specializations > Inflammation
,
Clinical and Disease Specializations > Autoimmunity
,
Clinical and Disease Specializations > Inflammation > Chronic Inflammatory Diseases
,
Clinical and Disease Specializations > Inflammation > Arthritis
,
Clinical and Disease Specializations > Inflammation > Tissue/Organ Transplant Rejection
,
Clinical and Disease Specializations > Gastroenterology > Crohn's Disease
,
Clinical and Disease Specializations > Gastroenterology > Ulcerative Colitis
,
Clinical and Disease Specializations > Gastroenterology > Inflammatory Bowel Disease
,
Clinical and Disease Specializations > Gastroenterology > Irritable Bowel Disease
Mimetic peptides derived from collagen type IV for the treatment of angiogenesis-dependent diseases
C11348: Novel Anti-Angiogenic Collagen Derived Mimetic PeptidesNovelty:modified peptides from collagen IV derived parent peptide Pentastatin-1Value Proposition:The invention describes the synthesis of novel anti-angiogenic by substituting particular amino acids of the peptide Pentastatin-1 derived from collagen IV. Other advantages include:• Ability...
Published: 1/22/2026
|
Inventor(s):
Niranjan Pandey
,
Elena Rosca
,
Corban Rivera
,
Jacob Koskimaki
,
Amir Tamiz
,
Aleksander Popel
Keywords(s):
Biologics
,
Cancers
,
Disease Indication
,
Peptide
,
Protein
,
Single
,
Targeted Therapy
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
,
Therapy Type
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Oncology
,
Technology Classifications > Therapeutic Modalities > Biologics
,
Technology Classifications > Therapeutic Modalities > Proteins
,
Technology Classifications > Therapeutic Modalities > Targets
,
Technology Classifications > Therapeutic Modalities
Polymeric particles for sustained delivery of multimodal peptide therapeutics
Value Proposition· Stability: polymeric nanoparticle encapsulation increases and sustains peptide residence time, for increased accumulation in tissue vasculature and maximize treatment effects· Safety: use of nanoparticles reduces toxicity by confining peptide delivery to site of administration· Flexible formulation approaches: system's...
Published: 1/22/2026
|
Inventor(s):
Jordan Green
,
Aleksander Popel
,
Joel Sunshine
,
Ron Shmueli
,
Stephany Tzeng
,
Kristen Kozielski
Keywords(s):
Biologics
,
Drug Delivery Vehicle
,
Nucleic Acid
,
Peptide
,
Polymers
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers
,
Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms
,
Technology Classifications > Therapeutic Modalities > Biologics
,
Technology Classifications > Therapeutic Modalities > Peptides
,
Technology Classifications > Therapeutic Modalities
Novel monoclonal antibody inhibitors targeting potassium channel KCNK9
Unmet Need:KCNK9 is one of 15 mammalian subtypes in the highly conserved family of two-pore domain potassium channels (K2P). Under physiological conditions, KCNK9 is primarily expressed in the brain where it serves to maintain cellular membrane potentials. However, overexpression of KCNK9 has been detected in breast, lung, skin, and other cancers, and...
Published: 1/22/2026
|
Inventor(s):
John Laterra
,
Han Sun
,
Min Li
,
Amy Fulton
Keywords(s):
Antibodies
,
Biologics
,
Breast Cancer
,
Cancers
,
Disease Indication
,
Lung Cancer
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Respiratory Diseases
,
Clinical and Disease Specializations > Women's Health
,
Technology Classifications > Therapeutic Modalities > Antibodies
,
Technology Classifications > Therapeutic Modalities > Biologics
,
Clinical and Disease Specializations > Oncology
,
Technology Classifications > Therapeutic Modalities
,
Clinical and Disease Specializations > Oncology > Breast Cancer
,
Clinical and Disease Specializations > Oncology > Lung Cancer
A Novel and Unique Set of Human Antibodies to Human Resistin and to Human Resitin-like Molecule Beta (RELMB) that can be used to Target these Proteins in Human Disease
Unmet NeedAutoinflammatory responses, your body’s innate defense mechanism against infections and stressors, can become overactive and cause chronic inflammation in various tissues and organs. Inflammatory diseases affect more than 200 million people worldwide and include pulmonary hypertension, scleroderma, rheumatoid arthritis, pulmonary fibrosis,...
Published: 1/22/2026
|
Inventor(s):
Roger Johns
Keywords(s):
Antibodies
,
Biologics
,
Cardiovascular Diseases
,
Disease Indication
,
Hypertension
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Clinical and Disease Specializations
,
Technology Classifications > Therapeutic Modalities > Antibodies
,
Technology Classifications > Therapeutic Modalities > Biologics
,
Clinical and Disease Specializations > Cardiovascular
,
Technology Classifications > Therapeutic Modalities
,
Clinical and Disease Specializations > Cardiovascular > Hypertension
CRISPR/Cas9 and Tumor-Specific Guide RNAs as a Specific and Selective Cancer Cell Killing Biologic Platform
Value Proposition:Specific targeting of mutations can treat any cancer with the specified mutations.Selective cell killing spares healthy tissue while eliminating cancer cells. Pan-cancer efficacy as guide RNAs are developed to target a wide breadth of cancer-specific mutations.Lack of protospacer adjacent motif (PAM) sites in healthy host cells prevents...
Published: 1/22/2026
|
Inventor(s):
James Eshleman
,
Selina Shiqing Teh
,
Kirsten Bowland
,
Nicholas Roberts
Keywords(s):
Category(s):
Clinical and Disease Specializations > Oncology
,
Clinical and Disease Specializations > Oncology > Pancreatic Ductal Adenocarcinoma
,
Clinical and Disease Specializations > Oncology > Pancreatic Cancer
,
Technology Classifications > Therapeutic Modalities > Biologics
,
Technology Classifications > Research Tools > Nucleic Acids
Cell-Permeable Protein Therapeutic for Pain and Itch
Novelty:Identification of a mutant peptide with strong inhibitory effect on nociceptor TRPA1, useful for the prevention and treatment of chronic and acute pain and itch.Value Proposition:Dysregulation of ion channels is associated with various debilitating conditions, including chronic pain and itch. Transient receptor potential ankyrin 1 (TRPA1), an...
Published: 1/22/2026
|
Inventor(s):
Hao-Jui Weng
,
Xinzhong Dong
Keywords(s):
Biologics
,
Biomarker
,
Chronic Pain
,
CNS and Neurological Disorders
,
Disease Indication
,
Mechanism of Action Biomarker
,
Peptide
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Neurology
,
Technology Classifications > Therapeutic Modalities > Biologics
,
Technology Classifications > Therapeutic Modalities > Peptides
,
Technology Classifications > Diagnostics > Biomarkers
,
Technology Classifications > Therapeutic Modalities > Targets
,
Technology Classifications > Diagnostics
,
Clinical and Disease Specializations > Pain
,
Technology Classifications > Therapeutic Modalities
,
Clinical and Disease Specializations > Pain > Chronic Pain
Transgenic Fungi that Kill Malaria Parasites in Mosquitoes
Invention novelty: This material is a transgenic fungus which targets the sporozoites that cause malaria in the salivary glands of mosquitoes. The fungus is taken up by direct contact with the mosquito and inhibits Plasmodium development. Value Proposition: Unmodified, Metarhizium anisopliae kills mosquitoes slowly. If mosquitoes are infected by the...
Published: 1/22/2026
|
Inventor(s):
Raymond St. Leger
,
Angray Kang
,
Weiguo Fang
,
Marcelo Jacobs-Lorena
Keywords(s):
Biologics
,
Disease Indication
,
Disease Management System
,
Healthcare Management
,
Infectious Diseases
,
Malaria
,
Operations Management
,
Parasitic Infections
,
Protein
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Clinical and Disease Specializations
,
Technology Classifications > Computers, Electronics & Software > Clinical Management
,
Technology Classifications > Computers, Electronics & Software > Healthcare IT
,
Technology Classifications > Therapeutic Modalities > Biologics
,
Technology Classifications > Therapeutic Modalities > Proteins
,
Technology Classifications > Computers, Electronics & Software
,
Clinical and Disease Specializations > Infectious Diseases
,
Technology Classifications > Therapeutic Modalities
,
Clinical and Disease Specializations > Infectious Diseases > Malaria
,
Clinical and Disease Specializations > Infectious Diseases > Parasitic Infections
Engineered Cytokine-antibody Fusion for Targeted Expansion of Immune Effector Cells
Unmet NeedGlobal revenue from the cytokine therapeutics market was valued at approximately $16.5 billion in 2018, and cytokine immunotherapy is a promising field of anti-cancer treatments for a broad range of cancer types. In particular, interleukin-2 (IL-2) therapy is shown to stimulate anti-cancer immunity. However, IL-2 activates contradictory immune...
Published: 1/22/2026
|
Inventor(s):
Jamie Spangler
,
Jakub Tomala
,
Michael Leff
,
Seth Ludwig
,
Elissa Leonard
,
Marek Kovar
,
Jirina Kovarova
Keywords(s):
Biologics
,
Cancers
,
Disease Indication
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Technology Classifications > Therapeutic Modalities > Antibodies
,
Clinical and Disease Specializations > Oncology
,
Technology Classifications > Therapeutic Modalities > Immunotherapies
,
Technology Classifications > Therapeutic Modalities > Biologics
Bioreducible Poly(beta-amino ester)s for siRNA Delivery
C12218: Efficient Delivery Vehicle for Controlled Gene Knockdown Novelty: This technology comprises the use of bioreducible polymer based nanoparticle system that can release siRNA cargo to the cytoplasm of cells to knockdown target gene expression in tissues. Value Proposition: Gene therapy is a developing medical field and there is a need for...
Published: 1/22/2026
|
Inventor(s):
Jordan Green
,
Stephany Tzeng
,
Kristen Kozielski
Keywords(s):
Biologics
,
Brain Cancer
,
Cancers
,
Cell Therapy
,
Disease Indication
,
Drug Delivery Vehicle
,
Glioma
,
Nucleic Acid
,
Polymers
,
Single
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
,
Therapy Type
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Neurology
,
Technology Classifications > Therapeutic Modalities > Biologics
,
Technology Classifications > Therapeutic Modalities > Gene Therapies
,
Technology Classifications > Therapeutic Modalities > Cell Therapies
,
Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers
,
Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms
,
Clinical and Disease Specializations > Oncology
,
Technology Classifications > Therapeutic Modalities
,
Clinical and Disease Specializations > Oncology > Brain Cancer
,
Clinical and Disease Specializations > Oncology > Glioma
1
2
3
4
5
6
7
8
9
10
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum